Noise

Sector: Pharma & Healthcare (Fitness Wearables & Continuous Glucose Monitoring (CGM) Plant)  |  HQ: India  |  Founded: Not separately disclosed  |  Employees: Not separately disclosed

Listed as: Privately held  | 

Company overview

Noise operates in the pharma & healthcare segment of the Indian market, with a presence noted in the fitness wearables & continuous glucose monitoring (cgm) plant category. The company is among the recognised participants in this segment alongside other Indian and multinational players. Operations follow the standard Companies Act 2013 disclosure framework where Noise is incorporated as a private or public limited company under Indian law, with statutory audit, GST registration under the CGST Act 2017, and applicable sectoral compliance under FSSAI, BIS, MoEF, or sectoral regulators as relevant to the activity. The competitive set in fitness wearables & continuous glucose monitoring (cgm) plant includes pan-India brands, regional players, and multinational subsidiaries operating in India through wholly-owned or joint-venture structures.

Recent developments

May 2026

The wearables segment in India continues to expand, with new product launches targeting the fitness audio category. OPPO introduced its Enco Air5 Pro earbuds in India, featuring up to 55dB active noise cancellation (ANC) and LHDC 5.0 audio support at a competitive price point of Rs. 4,999, indicating sustained competition in the budget-to-mid-tier noise-cancellation market [2]. This launch underscores growing consumer demand for advanced noise management features in personal audio devices.

Broader market sentiment in India remains oriented toward long-term fundamentals rather than short-term volatility. Analysts have advised investors to ignore market noise and maintain focus on structural growth drivers [7]. Meanwhile, discussions around economic growth emphasize confronting data-driven realities [4], suggesting a shift toward evidence-based policy and market evaluation that may benefit sectors like healthcare and wearables over speculation.

Sources (3)

1. OPPO Enco Air5 Pro with up to 55dB ANC, LHDC 5.0 launched in India for Rs. 4,999 - FoneArena.com · FoneArena.com · Thu, 21 May 2026
2. For economic growth, the first step is to confront the facts - The Indian Express · The Indian Express · Mon, 18 May 2026
3. Ignore market noise, India’s long-term story intact, say D-Street bulls Ramesh Damani and Sunil Singhania - The Economic Times · The Economic Times · Sat, 09 May 2026

Financial performance and recent trajectory

Disclosed revenue (FY25): Not separately disclosed in segment-wise FY 2024-25 reporting.

Competitive position

Noise occupies a position in the fitness wearables & continuous glucose monitoring (cgm) plant category alongside other listed and unlisted Indian players. Competitive intensity in the segment is shaped by raw material cost cycles, distribution depth, branded versus unbranded share, and the regulatory framework governing manufacturing, FSSAI labelling (for food), BIS standards (for engineering goods), or sectoral norms. The principal competitive moats in this category are typically scale, distribution reach, brand trust, and integrated procurement. KAMRIT's project report on fitness wearables & continuous glucose monitoring (cgm) plant benchmarks new entrant economics against the listed peer cost structure including capex per tonne (or per unit of output), working capital intensity, gross margin band, and the EBITDA delta between organised and unorganised participants.

Key risks

Input cost volatility in the fitness wearables & continuous glucose monitoring (cgm) plant value chain Competitive intensity from larger Indian groups and multinational subsidiaries Regulatory tightening under FSSAI, BIS, environmental norms, or labour codes

Outlook

Noise is a participant in the Indian fitness wearables & continuous glucose monitoring (cgm) plant category, which forms part of the broader Pharma & Healthcare space. The Indian fitness wearables & continuous glucose monitoring (cgm) plant market continues to evolve with rising organised share, premiumisation, distribution expansion, and a regulatory architecture covering the Companies Act 2013, the Income Tax Act 1961, the CGST Act 2017, the Legal Metrology Act 2009, and sectoral statutes including the Food Safety and Standards Act 2006 (for food and beverage subsegments), the Drugs and Cosmetics Act 1940 (for pharmaceutical or healthcare adjacencies), the Environment Protection Act 1986 (for emissions and effluents), and labour codes consolidated under the four 2020 labour codes. In KAMRIT's project report framework for this category, the competitive set typically includes pan-India branded leaders, multinational subsidiaries, mid-sized regional players, and a long tail of MSME participants. The structural attractiveness of the category for new entrants is a function of (a) market growth rate, (b) the share that remains with unorganised or fragmented operators, (c) the cost of regulatory compliance, and (d) the capex intensity of plant and machinery. The KAMRIT bankable DPR for this category structures a new entrant's economics against this competitive landscape. For Noise specifically, public-domain disclosures provide a baseline view of operations, but segment-wise revenue, EBITDA, capacity utilisation, and forward capex plans are not separately broken out in many cases. Where the company is part of a listed group, the SEBI LODR and the Companies Act 2013 governance framework apply, with statutory audit conducted under SA 700 and CARO 2020 reporting. Where the company is unlisted, the Companies Act 2013 framework continues to govern with reduced public disclosure. The risk and opportunity outlook for Noise mirrors the broader fitness wearables & continuous glucose monitoring (cgm) plant category dynamics. Demand-side drivers include rising household consumption, urbanisation, organised retail expansion, and policy support including PLI schemes (where applicable to the segment). Supply-side risks include input cost volatility, regulatory tightening, environmental compliance escalation, and competitive intensity from larger groups or imports. Management quality, balance sheet strength, distribution depth, and the capex execution track record are the differentiators within the peer set. KAMRIT's research desk maintains a baseline reference for Noise as a peer benchmark within the fitness wearables & continuous glucose monitoring (cgm) plant category. For investors, lenders, or new entrant promoters seeking a fuller assessment of Noise, KAMRIT's deep-dive company profile engagement covers financial trajectory, capacity and capex, distribution and customer concentration, regulatory exposure, and the competitive position with named peers.

KAMRIT point of view

Building or competing with Noise?

KAMRIT advises promoters, family offices, and global enterprises evaluating greenfield entry into the pharma & healthcare (fitness wearables & continuous glucose monitoring (cgm) plant) sector. Our Bankable DPR with Cost Model and ROI benchmarks your project economics against the listed-company cost structure of Noise and peers. The Execution Partnership tier covers everything from incorporation through commissioning. A 20-minute scoping call with our partners is free.

View all 1 related project report → Book a scoping call

Related KAMRIT project reports

These reports use Noise in benchmarking and competitive analysis sections.

Disclaimer: This profile is compiled by KAMRIT Financial Services LLP for educational and benchmarking purposes only. It is not investment advice, a recommendation to buy or sell securities, or a solicitation. Stock data is provided by Yahoo Finance and may be delayed by up to 20 minutes. Company financial commentary draws on publicly available filings, exchange disclosures, and KAMRIT industry research. Readers should consult a SEBI-registered investment adviser before making investment decisions. KAMRIT is a financial services and compliance firm, not a SEBI-registered investment adviser.